Journal of Aerosol Medicine and Pulmonary Drug Delivery

Scope & Guideline

Delivering insights for a healthier tomorrow.

Introduction

Immerse yourself in the scholarly insights of Journal of Aerosol Medicine and Pulmonary Drug Delivery with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1941-2711
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2008 to 2024
AbbreviationJ AEROSOL MED PULM D / J. Aerosol Med. Pulm. Drug Deliv.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The Journal of Aerosol Medicine and Pulmonary Drug Delivery focuses on advancing the science and application of aerosol-based therapies, particularly in the domain of respiratory medicine. The journal encompasses a multidisciplinary approach that includes pharmacology, engineering, and clinical studies to enhance drug delivery systems and their efficacy in treating respiratory conditions.
  1. Aerosol Drug Delivery Systems:
    Research in this area includes the development and optimization of various aerosol drug delivery devices, such as metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs). Studies often focus on how device characteristics influence drug delivery efficiency and patient outcomes.
  2. Pharmacokinetics and Pharmacodynamics of Inhaled Medications:
    This includes investigations into the absorption, distribution, metabolism, and excretion of inhaled drugs. Understanding the pharmacokinetic profiles of medications delivered via aerosols is crucial for optimizing dosing regimens and therapeutic efficacy.
  3. Innovative Formulation Development:
    Research on novel formulations, including liposomal, nanoparticle, and polymer-based systems, aims to enhance the stability, solubility, and delivery of active pharmaceutical ingredients (APIs) through inhalation.
  4. Clinical Outcomes and Patient-Centric Studies:
    The journal emphasizes studies that evaluate the clinical effectiveness of aerosol therapies in real-world settings, focusing on patient adherence, usability of inhalation devices, and overall treatment outcomes.
  5. In Vitro and In Vivo Models:
    A significant portion of research employs advanced in vitro and in vivo models to simulate respiratory conditions and assess aerosol deposition, drug efficacy, and safety profiles.
The Journal of Aerosol Medicine and Pulmonary Drug Delivery has witnessed a dynamic evolution in its thematic focus, reflecting emerging trends in aerosol therapy and respiratory medicine. Recent publications indicate a strong inclination towards innovative technologies and novel therapeutic approaches.
  1. Nanoparticle and Nanotechnology Applications:
    Increasing interest in the use of nanoparticles for drug delivery, particularly for targeting lung diseases such as tuberculosis and cancer, highlights a shift toward more sophisticated and effective inhalation therapies.
  2. Personalized Medicine Approaches:
    Research into personalized inhalation therapies that consider individual patient characteristics and preferences is gaining traction, indicating a move towards more tailored therapeutic strategies.
  3. Impact of E-Cigarettes and Vaping on Respiratory Health:
    With the rise in vaping, studies examining the effects of e-cigarette aerosols on respiratory function and health outcomes are becoming more prevalent, reflecting public health concerns.
  4. Advanced In Vitro Models for Drug Testing:
    The development of sophisticated in vitro systems that mimic human respiratory conditions for drug testing is emerging as a critical area of research, enhancing the predictive value of preclinical studies.
  5. Sustainability in Aerosol Delivery Devices:
    There is a growing focus on developing environmentally sustainable inhaler technologies, particularly in response to regulatory pressures and public demand for greener pharmaceutical practices.

Declining or Waning

While the journal continues to explore a broad range of topics related to aerosol medicine, certain themes appear to be declining in prominence over recent years. These waning scopes may reflect shifts in research focus or advancements in technology that render previous areas less critical.
  1. Traditional Nebulization Techniques:
    Research on conventional nebulizer systems appears to be declining as newer technologies, such as vibrating mesh nebulizers and soft mist inhalers, gain popularity for their efficiency and patient convenience.
  2. Non-Inhalation Drug Delivery Methods:
    There is a noticeable decrease in studies focusing on non-inhalation methods of drug delivery within the context of aerosol medicine, as the field shifts towards optimizing inhaled therapies specifically.
  3. Basic Aerosol Science without Clinical Application:
    While foundational aerosol science remains relevant, there seems to be a waning interest in purely theoretical studies that do not directly contribute to clinical applications or improvements in patient care.
  4. Pharmacokinetics of Non-Respiratory Drugs:
    Research focused on the pharmacokinetics of drugs not intended for respiratory diseases has diminished, as the journal's emphasis shifts towards inhaled therapies specifically tailored for respiratory conditions.

Similar Journals

Turkish Thoracic Journal

Connecting global insights to Turkish thoracic challenges.
Publisher: AVESISSN: Frequency: 6 issues/year

Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.

FARMACIA

Elevating Research Standards in the Pharmaceutical Realm.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

International Journal of Pharmacology

Connecting Laboratory Discoveries to Clinical Practice
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Empowering research to enhance eye disease treatments.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Expert Opinion on Drug Delivery

Delivering Expertise to Enhance Therapeutic Advancements
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5247Frequency: 12 issues/year

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Journal of Reports in Pharmaceutical Sciences

Fostering Excellence in Pharmaceutical Science Reporting.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Asian Journal of Pharmaceutical Research and Health Care

Advancing Pharmaceutical Knowledge for a Healthier Tomorrow
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2250-1444Frequency: 4 issues/year

Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

Advanced Pharmaceutical Bulletin

Leading the Charge in Pharmaceutical Innovation and Discovery
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Innovative Insights for Enhanced Drug Formulation and Safety.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

European Journal of Pharmacology

Exploring the frontiers of therapeutic applications and drug development.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.